Synthesis of 1,10-Phenanthroline Compounds Containing Azolium Salts and Studies on Their Anticancer Activity
Project no. 32327 · Status: Kapanmış · 2024
Summary
<p>Cancer is the most common disease, claiming hundreds of thousands of lives worldwide. According to the WHO, cancer cases are expected to rise to 22 million in the next twenty years. Due to the rapid increase in cancer cases globally, a proper understanding of the disease and the development of new, effective, non-toxic, and cheaper drugs for treatment are crucial. Currently, platinum and its derivatives are used in cancer treatment. However, these platinum complexes become ineffective as cells develop resistance to these drugs over time; they also exhibit serious side effects such as nephrotoxicity, neurotoxicity, ototoxicity, nerve damage, hair loss, nausea, vomiting, and abdominal pain. Ruthenium complexes are a new generation of metal anti-tumor drugs currently attracting significant attention in multidisciplinary research. Studies suggest that ruthenium complexes penetrate tumor cells well and bind effectively to DNA. Ruthenium complexes are currently of great interest as anticancer agents in the fields of biology, pharmaceuticals, and medicinal chemistry. The intercalation properties of the phenanthroline ligand into the DNA helix, the electronic and biological properties of imidazole derivatives, and the cytotoxic properties of ruthenium metal inevitably lead to the emergence of highly active species. This project aims to synthesize new and effective Ru(II) paracimene monometallic complexes containing phenanthroline and imidazole derivatives, which are not currently reported in the literature, and to investigate their cytotoxic properties in cancerous cell lines. The structures of the synthesized ruthenium complexes will be characterized using FTIR, 1H, 13C, 19F, 31P NMR spectroscopy, UV-visible spectroscopy, mass spectroscopy, and XRD analysis. The antitumor properties of the synthesized and characterized complexes will be evaluated in vitro using human breast cancer cell line (MCF-7), triple-negative breast cancer cell line (MDA-MB-231), and non-tumorigenic epithelial cell line (MCF-10A). The cytotoxic activity of each Ru-monometallic complex against cancer cells will be determined at four different concentrations using MTT (3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide) analysis. To evaluate the synthesized ruthenium complexes as potent cytotoxic agents, their ability to bind DNA and serum albumin and enter cells, their effect on apoptosis and autophagy proteins using western blot, and the stage of cell death, particularly apoptosis, will be investigated using Annexin V-FITC/PI. This project will reveal the effective role of metal-based drugs in the treatment of breast cancer within the field of medical bioinorganic chemistry, through approaches to the design and application of innovative metal-based drugs.</p>